Patents Assigned to ChemoCentryx, Inc.
  • Patent number: 11890276
    Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: February 6, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Petrus Bekker, Shichang Miao, Israel Charo, Tom Schall
  • Patent number: 11884654
    Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: January 30, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Trevor T. Charvat, Junfa Fan, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Venkat Reddy Mali, Jeffrey P. McMahon, Jay Powers, Sreenivas Punna, Ju Yang
  • Patent number: 11883391
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 30, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: James Campbell, Israel Charo, Thomas Schall, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Patent number: 11872217
    Abstract: Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a?, R2b?, R2c?, R3?, R4?, R5?, R6a?, R6b?, Y, Y?, and the subscripts m and n are as defined herein.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: January 16, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Viengkham Malathong, Venkat Reddy Mali, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Ju Yang, Penglie Zhang
  • Patent number: 11866429
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: January 9, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
  • Patent number: 11845729
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: December 19, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Patent number: 11844790
    Abstract: Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: December 19, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Shijie Li, Rajinder Singh, Thomas J. Schall, Peter Staehr
  • Patent number: 11834452
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: December 5, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Patent number: 11820759
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: November 21, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Antoni Krasinski, Manmohan Reddy Leleti, Venkat Mali, Jeffrey McMahon, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • Patent number: 11807609
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: November 7, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Rebecca M. Lui, Venkat Reddy Mali, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Patent number: 11793771
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 13, 2022
    Date of Patent: October 24, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Christopher Lange, Viengkham Malathong, Darren J. McMurtrie, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
  • Patent number: 11779576
    Abstract: Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: October 10, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventor: Petrus Bekker
  • Patent number: 11773091
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: October 3, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Patent number: 11759458
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: September 19, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Christopher Lange, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
  • Patent number: 11759454
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: September 19, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Xi Chen, Pingchen Fan, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang, Dean Dragoli
  • Patent number: 11744822
    Abstract: The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: September 5, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Israel Charo, Heiyoun Jung, Thomas J. Schall, Penglie Zhang
  • Patent number: 11713307
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: August 1, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
  • Patent number: 11708326
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: July 25, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Christopher Lange, Viengkham Malathong, Venkat Reddy Mali, Jeffrey McMahon, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Yu Wang, Ju Yang, Penglie Zhang
  • Patent number: 11691985
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: July 4, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Viengkham Malathong, Jeffrey McMahon, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Penglie Zhang
  • Patent number: 11684606
    Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: June 27, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: James J. Campbell, Karen Ebsworth, Antoni Krasinski, Venkat Reddy Mali, Jeffrey McMahon, Rajinder Singh, Ju Yang, Chao Yu, Penglie Zhang